ライフサイエンスコーパス: oral

1 ificantly higher than that of other sources: oral (3.89; 95% confidence interval [CI], 1.43-10.57), u

2 Experimental treatments were given with oral 5 mg/kg isoniazid and 25 mg/kg pyrazinamide per day

3 by a centralised computer system to receive oral acarbose (50 mg three times a day) or matched place

4 Intravenous sodium bicarbonate and oral acetylcysteine are widely used to prevent acute kid

5 Our data demonstrate that oral acrolein exposure in mice caused damage to the inte

6 HEDS II showed that oral acyclovir decreased the recurrence of any type of h

7 Oral adhesions can result from a disruption of periderm

8 t the molecular level, the sites of abnormal oral adhesions maintained periderm-like cells that expre

9 dulatory effects in vitro, but not following oral administration in humans.

10 ibutes to a concentration-time profile after oral administration in the cynomolgus monkey that showed

11 Oral administration of azithromycin definitively decreas

12 Oral administration of Cu(II)(atsm) delayed the onset of

13 r intestinal homeostasis abnormalities after oral administration of dextran sodium sulfate (DSS).

14 Oral administration of ERG240 reduces the severity of co

15 Oral administration of ovalbumin (OVA) in Was(-/-) mice

16 Oral administration of the plasmid DNA (pDNA) encoding G

17 Oral administration of vancomycin greatly dampened both

18 to determine the immunomodulatory effect of oral administration of vitamin D-enriched mushrooms extr

19 properties of this tracer mean that through oral administration, the turnover and flux through a num

20 ) were tested as Lf encapsulation system for oral administration.

21 ,4-dinitrobenzenesulfonic acid in rats after oral administration.

22 subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 mon

23 odel, we elucidate a novel mechanism whereby oral AM80 administration suppressed lung mucosa-associat

24 Pulmonary SCFAs correlated with increased oral anaerobes, such as Prevotella in the lung, and with

25 rgical incision or positioning that required oral analgesics for longer than 3-4 days after surgery (

26 aches to the case management of cholera with oral and intravenous rehydration therapy have reduced th

27 a (HNSCC) includes epithelial cancers of the oral and nasal cavity, larynx, and pharynx and accounts

28 , mainly salivary and lacrimal, resulting in oral and ocular dryness, although virtually any organ sy

29 rition Examination Survey and had results of oral and penile HPV DNA testing were examined.

30 galization in some countries, poses emergent oral and periodontal health concerns.

31 ey recommendations include administration of oral and, as necessary, intravenous hydration; systemati

32 espiratory tract infection and prescribed an oral antibiotic between January 2015 and April 2016 in a

33 f embolic stroke of undetermined source, and oral anticoagulant drugs may prove to reduce stroke risk

34 ion (P for heterogeneity = .49) or the novel oral anticoagulant type (P for heterogeneity = .15).

35 Oral anticoagulant use increased in the intervention gro

36 The availability of direct oral anticoagulants (DOACs) may improve overall OAC rate

37 assess the risk and benefit of non-vitamin K oral anticoagulants among patients at high risk for stro

38 specific comparative effectiveness of direct oral anticoagulants among patients with nonvalvular atri

39 major gastrointestinal bleeding with direct oral anticoagulants compared with warfarin or low-molecu

40 the risk of intraocular bleeding with novel oral anticoagulants compared with warfarin.

41 the risk of intraocular bleeding with novel oral anticoagulants differs compared with warfarin.

42 These results suggest that novel oral anticoagulants reduce the risk of intraocular bleed

43 wer risks of intraocular bleeding with novel oral anticoagulants were seen in subgroup analyses, with

44 al BPV thrombosis and the value of empirical oral anticoagulation following BPV implantation.

45 Not having oral anticoagulation prescribed at baseline and having A

46 nt at follow-up and resolved after increased oral anticoagulation with warfarin.

47 anasal corticosteroid in combination with an oral antihistamine.

48 thrombotic effect during a window of limited oral antiplatelet action.

49 Oral antiviral therapy alone without hepatitis B immune

50 idence supporting the use of intravenous and oral antiviral therapy for the treatment of ARN.

51 n Matameye, Niger, were randomized to annual oral azithromycin treatment of the entire community or b

52 Adverse reactions to oral azoles, drug interactions, and azole resistance in

53 Oral bacteria were assessed using 16S rRNA gene sequenci

54 n vitro, including some of those produced by oral bacteria.

55 we show here that diabetes causes a shift in oral bacterial composition and, by transfer to germ-free

56 modium infections as well as to systemic and oral bacterial infections.

57 resistant and susceptible to infection with oral bacterial pathogens.

58 Oral bacteriotherapy thus has potential in the treatment

59 mediating immune surveillance at a specific oral barrier, the gingiva - a constantly stimulated and

60 le-blind fashion to either extended-duration oral betrixaban (80 mg once daily for 35-42 days) or sta

61 ug of cidofovir, brincidofovir, has improved oral bioavailability and achieves higher intracellular c

62 still has some issues including solubility, oral bioavailability and cost of preparation.

63 In this study, PK parameters and absolute oral bioavailability expressed as percentage (F%) of cel

64 d promutagenic potential as well as very low oral bioavailability in rats (F = 2%) and was therefore

65 However, high instability and extremely low oral bioavailability limit its further clinical developm

66 g through Lipinski's rule of five filter for oral bioavailability, ADMET risk filter for drug like fe

67 erate pharmacokinetic properties and limited oral bioavalability of 18.7% in rats.

68 imicrobial agents after attachment or within oral biofilms, resulting in their disruption.

69 Oral biotherapy with TLR4 ligands might be useful to pot

70 ndomly assigned (1:1) to receive second-line oral buparlisib (100 mg once daily) or placebo, plus int

71 Participants received oral cabotegravir 30 mg tablets or matching placebo once

72 and sequencing (RIP-seq) analyses of HuR in oral cancer cells treated with ionizing radiation (IR),

73 al growth factor receptor (EGFR) therapy for oral cancer does not provide satisfactory efficacy due t

74 ased glutamate metabolism metal transport in oral cancer patients.

75 nd EGFR could potentially offer an effective oral cancer therapy.

76 with poor oral hygiene, tobacco smoking, and oral cancer.

77 tumour recurrence (TTR); and whether use of oral capecitabine instead of cyclophosphamide would be n

78 nosis and potential therapeutic strategy for oral carcinoma.

79 ottic secretion drainage endotracheal tubes, oral care, chlorhexidine mouth care, and daily spontaneo

80 ctinomycetemcomitans infection in the murine oral cavity and to prevent subsequent alveolar bone dest

81 eir findings highlight the importance of the oral cavity as a potential reservoir for bacteria that c

82 the epithelium and mesenchyme in the base of oral cavity as compared to the palate and posterior tong

83 d mucoadhesion of liquid formulations in the oral cavity but it is also the first to link the mucoadh

84 cture of this community, suggesting that the oral cavity may be less susceptible to dysbiosis during

85 ltivated mycoplasma (lineage 'Mnola') in the oral cavity of a premature neonate.

86 enotype was 45.3% on the penis, 11.2% in the oral cavity, and 8.8% at both sites.

87 d KLFs in the digestive system including the oral cavity, esophagus, stomach, small and large intesti

88 Mucosal sites such as the intestine, oral cavity, nasopharynx, and vagina all have associated

89 863 patients with newly diagnosed SCC of the oral cavity, oropharynx, larynx, or nasopharynx was used

90 their cytotoxicity on cells belonging to the oral cavity.

91 d to the development of the cement gland and oral cavity.

92 uding those of the anogenital region and the oral cavity.

93 rios that involve critical structures in the oral cavity.

94 of high value for cancers of the larynx and oral cavity.

95 and also shows younger ages at diagnosis of oral cavity/pharynx and kidney cancers, possibly reflect

96 ophylaxis, a postoperative 48-hour course of oral cephalexin and metronidazole, compared with placebo

97 ) followed by epicutaneous sensitization and oral challenge of their offspring with OVA.

98 might allow to make a considerable number of oral challenges superfluous.

99 om two retrospective studies, support use of oral cholera vaccine in pregnant women in cholera-affect

100 Killed whole-cell oral cholera vaccines (kOCVs) are becoming a standard ch

101 onsistently detected self-limited, low-level oral CMV shedding events, which we termed transient CMV

102 ciated with current or recent use of various oral combination (estrogen-progestin) contraceptives var

103 ability in viral suppression relative to the oral comparator group.

104 impact of BBS on the anatomic development of oral components and oral pathology encountered in the co

105 In general, the oral conditions greatly affected the antioxidants, while

106 An oral corticosteroid treatment was started.

107 Treatment with oral corticosteroids may help to reduce the risk of CNVM

108 The effect of oral corticosteroids on FEV1 , Pc20, airway inflammation

109 Among ICU patients with sepsis, preadmission oral corticosteroids were independently associated with

110 ents who initiated with mesalazine, 141 with oral corticosteroids, and 143 with intravenous corticost

111 d CCL-13 (MCP-4) in both asthma groups after oral corticosteroids.

112 -14.34], theophylline: 2.46 [1.23-4.91], and oral corticosteroids: [2.99;.1.26-7.08]).

113 ion with systemic chemotherapy therapies and oral corticosteroids; however, recurrences were common.

114 ological alterations associated with chronic oral corticosterone were investigated using male nonobes

115 nd after the administration of 0.5 mg kg(-1) oral D-amphetamine.

116 monstrates the use of non-viral vector based oral delivery of GLP-1 gene through enterohepatic recycl

117 olysaccharide nanogels are newly explored as oral delivery systems with promising encapsulation poten

118 N from all natural biomaterials as potential oral delivery vehicles.

119 are with acute sore throat, a single dose of oral dexamethasone compared with placebo did not increas

120 Current therapies with all-oral direct-acting antiviral agents are associated with

121 ited real-world data on the effectiveness of oral direct-acting antivirals (DAAs) in predominantly mi

122 of LT integrated data from recent trials of oral direct-acting antivirals (SOLAR 1 and 2), the Unite

123 rvations apply equally to the study of other oral diseases.

124 Single oral dose of 10 mg of dexamethasone (n = 293) or identic

125 ndomly assigned to receive either an initial oral dose of 200 000 IU (5.0 mg) colecalciferol (vitamin

126 (HFD) to mice for 10 weeks, followed by five oral dosing with purified AHC or ovalbumin on alternate

127 d total cholesterol levels in rats following oral dosing.

128 h lycopene may be a promising application in oral drug delivery in various indications.

129 is generally ideal for once daily dosing of oral drugs.

130 Further, compound 49 displayed oral efficacy in 6-OHDA lesioned rat model of Parkinson

131 -prostanoid IP receptor agonists that showed oral efficacy in the rat monocrotaline model of pulmonar

132 genetic effect, natural aging and prolonged oral environmental toxicity administered to mutant knock

133 jor CLP gene Irf6 only in the late embryonic oral epithelium ( Irf6 cKO), bypassing the role of the g

134 s assessed with VAS and the Questionnaire of Oral Esthetic Satisfaction.

135 However, oral estrogen treatment is controversial because of its

136 A total of 539 participants had oral examinations in 2013.

137 self, producing cures in mice after a single oral exposure.

138 combined to give significant improvements in oral exposure.

139 1 (SCLT1) mutations were associated with the oral-facial-digital syndrome (OFD), an autosomal recessi

140 ns in TMEM107 were previously connected with oral-facial-digital syndrome, Meckel-Gruber syndrome, an

141 Rivaroxaban, an oral factor Xa inhibitor, might simplify treatment compa

142 ize the cause of nutritional dyshomeostasis (oral failure, malabsorption, or both), and to quantify t

143 human knockouts and challenged them with an oral fat load.

144 was incapable of infecting mosquitoes after oral feeding of spiked-blood meals, representing an addi

145 In longitudinal trials, negative oral fluid results should be confirmed via testing of bl

146 a case of jellyfish allergy diagnosed via an oral food challenge.

147 cific IgE measurement, skin prick tests, and oral food challenges), and the timing and approaches for

148 Oral food intake did not differ between the 2 groups.

149 dine bioavailability by 100% as compared to oral gavage delivery.

150 estern diet (WD) +/-75 mg PDX twice daily by oral gavage for 14 days.

151 Mice were infected by means of oral gavage with 200 stage 3 H polygyrus larvae.

152 gE-mediated FA was induced in BALB/c mice by oral gavage with medium-chain triglycerides (MCTs) plus

153 given fungicide and donor cecum content via oral gavage.

154 The odds of a reduction in the oral glucocorticoid dose were more than 4 times as high

155 thma exacerbations, was also effective as an oral glucocorticoid-sparing therapy in patients relying

156 icoid-sparing therapy in patients relying on oral glucocorticoids to manage severe asthma associated

157 Furthermore, our results indicate that oral glucose consumption in the fasting state is followe

158 n of postchallenge change in glucagon during oral glucose tolerance tests (OGTTs), hypothesizing that

159 Oral glucose tolerance tests were administered at the sa

160 Here, we found that supplementation with oral glutamine reduced virus reactivation in latently HS

161 ulating gluten-specific CD4(+) T cells after oral gluten challenge of patients with celiac disease.

162 r double-blind crossover, placebo-controlled oral gluten challenge, which had a fixed sequence, and b

163 uantitative histology within 2 weeks without oral gluten challenge.

164 ly higher for the intravenous group than the oral group [odds ratio (OR) 1.74, 95% confidence interva

165 dicates a postive linear association between oral health and mortality.

166 aff) using an oral health checklist improves oral health behaviour or oral health state in those thou

167 -ordinators (largely nursing staff) using an oral health checklist improves oral health behaviour or

168 The Oral Health Impact Profile (OHIP-14) questionnaire was a

169 reastfeeding was among the first to consider oral health outcomes.

170 erefore, authors of systematic reviews using oral health randomized controlled trials should perform

171 checklist improves oral health behaviour or oral health state in those thought to be at risk of psyc

172 microbiome of 61 FA patients regarding their oral health status and OSCC risk factors.

173 ears), and full-mouth clinical parameters of oral health were assessed including periodontal, oral mu

174 e mix of bacteria that coat our teeth impact oral health, but it remains unclear what factors govern

175 models were used to evaluate the effects of oral health, general health, and socioeconomic character

176 Use of oral health-related data alone, especially in a young po

177 sociation between gingival bleeding (GB) and oral health-related quality of life (OHRQoL).

178 IV testing and treatment (Test & Treat), and oral HIV pre-exposure prophylaxis (PrEP).

179 ), (2) coupon (a coupon for collection of an oral HIVST from a health clinic/pharmacy), or (3) standa

180 rms: (1) delivery (direct distribution of an oral HIVST from the peer educator), (2) coupon (a coupon

181 The predicted probability of high-risk oral HPV infection was greatest among black participants

182 the observed association between penile and oral HPV infections.

183 Notably, the prevalence of oral HPV16/18/6/11 infections was significantly reduced

184 control group was treated with MI and given oral hygiene instructions.

185 Oral hygiene status was positively associated with the e

186 the oral microbiome were observed with poor oral hygiene, tobacco smoking, and oral cancer.

187 lopment and a significant role in regulating oral immunity.

188 Oral immunotherapy (OIT) has demonstrated reproducibly s

189 Rush oral immunotherapy is a treatment option to be considere

190 h a block size of four, to receive multifood oral immunotherapy to two to five foods, together with o

191 Despite progress in single food oral immunotherapy, there is little evidence concerning

192 isition of food allergen unresponsiveness in oral immunotherapy.

193 The deceased had fewer teeth and more oral infections.

194 Human jejunal digests after oral ingestion of casein and whey protein were collected

195 Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase (BTK), at a o

196 amined whether patients filled any alternate oral, injectable, or infusible anticancer agent within 9

197 gma was challenged in a report demonstrating oral insulin does not prevent T1D in NOD mice, possibly

198 in SUGEN-5416/hypoxia-induced PAH rats than oral, intravenous, or intratracheal plain sildenafil did

199 The oral introduction of glutamic acid increased virus acqui

200 tudy aim was to compare iron absorption from oral iron supplements given on consecutive versus altern

201 ion strategy.We measured the effect of daily oral iron with or without multiple micronutrients (MMNs)

202 failure with preserved ejection fraction to oral KNO3 (n=9) or potassium chloride (n=3).

203 We assessed barrier functions by the oral Lac:Man and the fecal zonulin tests.

204 matching placebo once daily during a 4 week oral lead-in phase, followed by a 1 week washout period

205 tive voice-response system to receive either oral lenalidomide (2.5 mg/day) or matching oral placebo

206 Oral leniolisib led to a dose-dependent reduction in PI3

207 te, within-subject, dose-escalation study of oral leniolisib to assess safety, pharmacokinetics, and

208 Indeed, curing HCV infection with an oral medication is now reality.

209 ists, otolaryngologists, dermatologists, and oral medicine specialists.

210 ne, and maintenance therapy comprising ATRA, oral methotrexate, and mercaptopurine.

211 aries can be described as a dysbiosis of the oral microbial community, in which acidogenic, aciduric,

212 s can significantly shift the ecology of the oral microbiome (at species level) resulting in a commun

213 ic units and taxonomy assigned via the Human Oral Microbiome Database, then analyzed at the community

214 The oral microbiome has numerous advantages that make it par

215 ies made in this area, it is unknown how the oral microbiome responds to short-term hospitalization.

216 nt shifts in composition and function of the oral microbiome were observed with poor oral hygiene, to

217 nt host inflammatory response to a dysbiotic oral microbiome.

218 and, by transfer to germ-free mice, that the oral microbiota of diabetic mice is more pathogenic.

219 this study, we examined the relationship of oral microbiota with EAC and ESCC risk in a prospective

220 se metabolism were analyzed according to the oral minimal model.

221 Two low-cost interventions-low-dose oral misoprostol tablets and transcervical Foley cathete

222 o the emergence of language in ways that the oral modality cannot.

223 length of hospital stay than treatment with oral morphine, with similar rates of adverse events.

224 Compared to skin, wound healing in oral mucosa is faster and produces less scarring, but th

225 health were assessed including periodontal, oral mucosal, and caries status in Eastern Finland from

226 an efficient technique facilitating ocular, oral mucosal, gastrointestinal, ungual and vaginal drug

227 nd web-response system, to receive 1 year of oral neratinib 240 mg/day or matching placebo.

228 sover trial assessed the effectiveness of an oral neurokinin 3 receptor antagonist (MLE4901) on menop

229 The practice of treating PAH patients with oral or intravenous sildenafil suffers from the limitati

230 00 mg or 900 mg per day according to weight, oral or intravenous) versus identical placebo, together

231 Use of a beta-lactam plus an oral or parenteral macrolide (azithromycin or clarithrom

232 0 mg intravenous zanamivir (n=209), or 75 mg oral oseltamivir (n=205) twice a day; 11 patients discon

233 venous zanamivir, or standard-of-care (75 mg oral oseltamivir) twice a day for 5-10 days; patients we

234 ght of 14 patients with CPr had at least one oral pathogen in their prostatic secretions.

235 are highlighted, emphasizing the spectrum of oral pathology associated with heterogeneous clinical ph

236 anatomic development of oral components and oral pathology encountered in the context of various BBS

237 has excellent microsomal stability and good oral pharmacokinetics in rats and mice.

238 r oral lenalidomide (2.5 mg/day) or matching oral placebo capsules (2.5 mg/day) for 28-day cycles, un

239 domly assigned patients to receive tDCS plus oral placebo, sham tDCS plus escitalopram, or sham tDCS

240 am tDCS plus escitalopram, or sham tDCS plus oral placebo.

241 1 mg/kg BW) were determined following single oral (PO) and intravenous (IV) administration to cockati

242 accination campaign with a monovalent type 2 oral polio vaccine (mOPV2).

243 Following vaccination with trivalent oral polio vaccine (tOPV) at 6, 10, and 14 weeks, infant

244 existing dynamic poliovirus transmission and oral poliovirus vaccine evolution model.

245 % received the third dose of pentavalent and oral poliovirus vaccine, respectively, but only 65% rece

246 e is non-inferior to standard treatment with oral prednisolone for short-term blister control in bull

247 P Study, a placebo-controlled trial of daily oral PrEP (either tenofovir monotherapy or a combination

248 These data are reassuring that oral PrEP delivery to women can continue without the nee

249 igh adherence to PrEP, the efficacy of daily oral PrEP for HIV prevention did not differ significantl

250 P costs were associated with higher rates of oral prescription abandonment and delayed initiation acr

251 e randomly assigned after a run-in period to oral ramipril 10 mg/day (n=8407), telmisartan 80 mg/day

252 ch long-acting regimen is not worse than the oral regimen proportion by more than 10% (denoted compar

253 The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to

254 Oral rinse, penile swab, and vaginal swab specimens were

255 ts were randomly assigned (1:1:1) to receive oral rivaroxaban (2.5 mg twice a day) plus aspirin (100

256 Despite its patient-friendliness, the oral route is not yet a viable strategy for the delivery

257 f MERS-like-CoVs mainly occurs via the fecal-oral route.

258 tract primarily transmissible via the fecal-oral route; (2) in the modern era, C. trachomatis causes

259 scrapie by both the intracerebral (i.c.) and oral routes, exploring the effects of polymorphisms at c

260 onducted the first population-wide survey of oral samples for an EBV-like virus in a nonhuman great a

261 The low detection rate of early oral SCC is a considerable clinical issue.

262 and Allied Health Literature, Dentistry and Oral Sciences Sources, and PubMed.

263 mission; and (3) the rise in the practice of oral sex is contributing to the increased prevalence of

264 g men who reported having 2 or more same-sex oral sex partners, the prevalence of high-risk HPV infec

265 who reported 16 or more lifetime vaginal or oral sex partners.

266 We characterized kinetics of oral shedding during primary and chronic infection for e

267 ontact ERBs by finding MARV RNA in blood and oral specimens from contact bats, followed by MARV IgG a

268 in 742 (71.8%) anal specimens and 101 (9.8%) oral specimens.

269 al chemical composition and structure in the oral spirochete Treponema denticola, a keystone pathogen

270 But the biological effect of SDT on oral squamous cell carcinoma has not been studied.

271 The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative efficacy

272 domization, patients were randomized between oral study medication and CBT (2:1) for 24 weeks.

273 randomized to receive 2000 IU/d of vitamin D oral supplementation (high-dose group) vs 354 participan

274 Daily oral supplementation with vitamin D3 (1000 IU) or calciu

275 dentists, endodontists, pediatric dentists, oral surgeons, orthodontists, and periodontists in small

276 We collected weekly oral swabs from young children and mothers in 32 Ugandan

277 SLIT with rMal d 1 reduced rMal d 1-induced oral symptoms (P = .001 and P = .038) accompanied by lon

278 idal infection that may give rise to painful oral symptoms, as well as be a reservoir for infection a

279 Daily oral tenofovir-based pre-exposure prophylaxis (PrEP) is

280 ctive HCV treatment for dual, triple, or all-oral therapy had a 30% decreased risk of developing CKD

281 clinical efficacy of fosfomycin as step-down oral therapy to treat complicated urinary tract infectio

282 meostasis at inductive and effector sites of oral tolerance by suppressing peripheral regulatory T ce

283 controlled trials exploring the efficacy of oral tolerance induction in infancy for the prevention o

284 Further studies that explore the efficacy of oral tolerance induction to other common food allergens

285 Oral tolerance induction was enhanced in mice lacking ex

286 h TLR4 ligands might be useful to potentiate oral tolerance to haptens and alleviate ACD in human sub

287 Induction of oral tolerance to haptens is an efficient way to prevent

288 Oral tolerance was induced by DNFB gavage in germ-free a

289 mproved sanitation/hygiene and reduced fecal-oral transmission; and (3) the rise in the practice of o

290 Oral treatment with enrofloxacin suppresses CS and produ

291 Oral vancomycin days of therapy decreased from an averag

292 n a multivariate analysis, failure to use an oral vancomycin taper preceding FMT was associated with

293 Eligible patients received oral venetoclax, starting at 20 mg per day with stepwise

294 assigned (1:1) to treatment group A (150 mg oral vismodegib per day for 12 weeks, then three rounds

295 smodegib daily) or treatment group B (150 mg oral vismodegib per day for 24 weeks, then three rounds

296 MUTT II showed that oral voriconazole did not improve outcomes overall, alth

297 , and physicians should consider prescribing oral voriconazole in these cases.

298 m keratitis may benefit from the addition of oral voriconazole to topical natamycin, and physicians s

299 eated patients with celiac disease underwent oral wheat challenge to stimulate recirculation of glute

300 ior management level and thus require robust oral, written, and interpersonal communication skills.